University of Thessaly (UTH)
Μελέτη της ειδικής χυμικής και κυτταρικής ανοσίας έναντι αυτοαντιγόνων σε ασθενείς με χρόνιες ηπατοπάθειες
Abstract
dc:descriptionPrimary Biliary Cirrhosis (PBC) is an autoimmune liver disease characterized by progressive inflamatory destruction of the small intrahepatic biliary ducts leading to cirrhosis and liver failure. The serologic hallmark of PBC is the presence of antimitochondrial antibodies (AMA). The main antigenic target of AMA is the E2 subunit of Pyruvate Dehydrogenase Complex (PDC-E2). Previous studies have addressed the central role of cellular immunity in the pathogenesis of the disease. Despite the evidence on the central role of cellular immunity against the PDC-E2 protein in the pathogenesis of PBC, so far, only one study by Shimota et al has adressed the CD4+ T cell epitopes of PDC-E2. In this study, the dominant epitope was described as a peptide within the inner lipoyl domain of the protein from amino acid 163 to amino acid 176 (PDC-E2163-176). However, it is unknown whether this epitope is dominant in PBC populations outside Japan. Moreover, it is unknown whether this peptide, is the only single epitope within the protein. To date, there is lack of information of the T and B- cell PDC-E2 epitopes in Caucasians and in particular among Greek PBC patients. Accordingly, our studies aimed to address the above questions. We initially characterize the AMA reactivity in 87 PBC patients showing that using multiple techniques for the detection of AMA the sensitivity is close to 100%. Eighty sixpercent (86.2%) of the patients were tested positive for IgG AMA using HEp-2 commercial substrate by indirect immunofluoresence (IIF) whereas 83.9% of the patientswhere tested positive for AMA by IIF on rat liver, kidney and stomach sections. AMA positivity was found in 90.1% of the PBC patients with either IIF method. Using a commercial MIT-3 ELISA, 89.6% of the patients were tested positive for IgG AMA where as 79.3% were tested positive for IgA AMA using the same substrate. A total of 93.1% of the patients showed positive reaction for either IgG or IgA AMA using the MIT-3 ELISA kit. Interestingly, 98.85% (86/87) of the patients tested positive for AMA for IIF and/or ELISA, indicating that the combination of these methods is the most effective way to detect AMA. To further identify immunodominant peptides of the PDC-E2 recognized by AMA in PBC, we initially used a recombinant part of the PDC-E2 containing the inner lippoyl domain to characterize humoral anti-PDC-E2 reactivity by western blot and in house ELISA. Sera from 19 PBC patients tested positive by ELISA against 76 synthetic overlapping peptides (20 amino acids; aa) covering the entire length of the PDC-E2. Humoral specific reactivity against the peptides 15 and 16 within the PDC-E2 outer lippoyl donain, was seen in 4 (21.05%) and 5 (26.31%) patients respectively. None of the controls tested positive against these peptides. Serum for only one patient showed reactinity against a peptide (peptide 26) within the PDC-E2 inner lipoyl domain. None of the sera showed reactivity against the peptides spanning the PDC-E2 Ε1/Ε3 binding domain. Sera from 13 out of 19 patients (68.42%) showed reactivity against at least one peptide within the catalytic domain. Four clusters of epitopes were recognized within the catalytic domain (peptides 51 and 52, 59, 64 and 72-74). The above results suggest a conformational epitope within the PDC-E2 inner lipoyl domain as 100% of the the patients showed reactivity against the protein containing the PDC-E2 inner lipoyl domain whereas only one patient reacted to a peptide within the inner lipoyl domain. However, the epitopes within the catalytic domain seem to be multiple and linear.Thirty five patients with PBC were studied to characterize the PDC-E2163-176 specific T cell immune responce with IFN-γ ELISpot. Only 3/35 (8.57%) showed statistically significant T cell reactivity against PDC-E2163-176. The CD4+ T cell responce against the PDC-E2163-176 was furthermore studied with flow cytometry after stimulating with the previously characterized epitope for 7 days Peripheral Blood Mononuclear Cells (PBMCs) from 21 patients. Two out of 21 patients (9.52%) showed statistically significant IFN-γ production. The differences of reactivity between patients and healthy controls was not statistically significant. Our data suggest that peptide PDC-E2163-176 is a subdominant epitope among Greek patients with PBC and a more systemic approach was necessary to identify the CD4+ T cell epitopes in this population. For this reason we used T-cell epitope prediction databases (SYFPEITHI) and programs that predict MHC-Ι and MHC-ΙΙ peptide binders from protein sequence or sequence alignments using Position Specific Scoring Matrices (Rankpep) to design 26 peptides according to our patient’s HLAs. These peptides were divided in 5 pools of peptides. Peripheral Blood Mononuclear Cells (PBMCs) from 21 patients and 5 healthy controls were stimulated with these pools and the T cell immune response was measured as antigen specific IFN-γ production using an IFN-γ ELISpot assay. Statistically significant IFN-γ production was identified in 8 patients (38.1%). Seven of these 8 patient showed reactivity against one pool and 1 showed reactivity against 3 pools. These results indicated that the larger the numbers of peptides used, the wider the identified reactivity is. For this reason, we aimed to create overlapping peptides spanning the entire PDC-E2 protein. CD4+ T cell reactivity among 22 patients was evaluated with flow cytometry detecting the antigen specific response after stimulating PBMCs with 12 pools of 76, 20aa overlapping peptides spanning the entire PDC-E2. CD4 antigen specific proliferation was also studied in 10 patients after stimulating their CFSE stained, antigen stimulated CD4+ T cells. CD4+ T lymphocytes from 17 out of 22 patients (77.27%) showed statistically significant production of IFN-γ after stimulation with at least one pool. Each patient showed a distrinct pattern of reactivity against different pools of peptides with the majority of patients reacting against to more than one pools. The CD4+ T lymphocytes of nine out of 10 patients also showed statistically significant antigen specific proliferation after being stimulated with at least one pool. The majority of patients showed significant antigen specific proliferation against multiple pools (mean 5.2). Our results indicate that the CD4+ T cell immune reactivity among Greek patients with PBC is heterogenous and polyclonal.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Spyrou, Elias
- Σπύρου, Ηλίας
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/34776